At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Naltrexone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Opioid Modulation and Neural Reward Activation in Healthy Adults
In Brief
A Phase 2 clinical trial evaluating Naltrexone and Placebo for Alcohol Drinking and Opioid Use, Unspecified. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This is a double blind study of the effects of opioid antagonism on the brain's reward response. The investigators will recruit participants to undergo two scans, one on active medication and one on placebo. During the scan, the investigators will assess reward.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Drinking, Opioid Use, Unspecified
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedApr 22, 2021
Enrollment StartMay 1, 2021
Primary CompletionApr 18, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.2 years ago
Interventions
Naltrexonedrug
Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
Placeboother
Placebo will be used to control for expectancy effects